Previous 10 | Next 10 |
-- Interim d ata from Phase 2 study showed that once-weekly formulation of setmelanotide achieve d safety and efficacy results comparable to daily-dosing formulation -- -- Additional data from long-term extension study in POMC deficiency obesity ...
Rhythm Pharmaceuticals (RYTM): Q3 GAAP EPS of -$0.77.Cash, cash equivalents and short-term investments of $201.8M.Shares are up 8.9% PM.Press Release For further details see: Rhythm Pharmaceuticals reports Q3 results
-- NDA for setmelanotide for POMC and LEPR deficiency obesities under review, with PDUFA goal date of November 27, 2020 -- -- Appointed Jennifer Chien and Yann Mazabraud to co-lead global integrated commercial strategies -- -- On track to announce topline data...
BOSTON, Oct. 30, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, announced today that results from two pivotal Phase 3 studie...
BOSTON, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that Jennifer Chien has been appointed as Ex...
– Company announces organizational changes designed to accelerate global strategy – BOSTON, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the...
BOSTON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that company management will present at tw...
Gainers: VBI Vaccines (NASDAQ: VBIV ) +35% . More news on: VBI Vaccines Inc., Rekor Systems, Inc., BMC Stock Holdings, Inc., Stocks on the move, , Read more ...
BOSTON, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that David Meeker, M.D., Chair, President a...
Rhythm Pharmaceuticals (NASDAQ: RYTM ) : Q2 GAAP EPS of -$0.71 beats by $0.12 . More news on: Rhythm Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Rhythm Pharmaceuticals Inc. Company Name:
RYTM Stock Symbol:
NASDAQ Market:
Rhythm Pharmaceuticals Inc. Website:
BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced the appointment of Alastair “Al...
- European Commission decision anticipated in the second half of 2024 - BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rar...
2024-06-14 11:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...